Systemic treatment of metastatic hormone-sensitive prostate cancer-upfront triplet versus doublet combination therapy.
作者信息
Oing C, Bristow R G
机构信息
Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK; Sir Bobby Robson Cancer Trials Research Centre, Northern Centre for Cancer Care, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Cancer Research UK Manchester Institute, University of Manchester, Manchester Cancer Research Centre, Manchester, UK.
出版信息
ESMO Open. 2023 Apr;8(2):101194. doi: 10.1016/j.esmoop.2023.101194. Epub 2023 Mar 21.
Abstract
摘要
相似文献
1
Systemic treatment of metastatic hormone-sensitive prostate cancer-upfront triplet versus doublet combination therapy.转移性激素敏感性前列腺癌的全身治疗——一线三联疗法与双联联合疗法对比
ESMO Open. 2023 Apr;8(2):101194. doi: 10.1016/j.esmoop.2023.101194. Epub 2023 Mar 21.
2
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis.三药联合或两药联合治疗转移性激素敏感型前列腺癌患者：系统评价和网络荟萃分析。
Eur Urol Focus. 2023 Jan;9(1):96-105. doi: 10.1016/j.euf.2022.08.007. Epub 2022 Sep 1.
3
[Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer].雄激素剥夺疗法联合化疗±雄激素受体靶向药物治疗转移性激素敏感性前列腺癌
Urologie. 2023 Apr;62(4):360-368. doi: 10.1007/s00120-023-02029-0. Epub 2023 Feb 10.
4
Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.雄激素受体信号抑制剂联合多西他赛与雄激素剥夺疗法治疗转移性激素敏感前列腺癌：系统评价和荟萃分析。
Eur Urol. 2022 Dec;82(6):584-598. doi: 10.1016/j.eururo.2022.08.002. Epub 2022 Aug 19.
5
Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options.在新型治疗选择时代转移性激素敏感前列腺癌的临床结局和种族差异。
Oncologist. 2021 Nov;26(11):956-964. doi: 10.1002/onco.13848. Epub 2021 Jun 29.
6
Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. PRO: docetaxel chemotherapy should be the default consideration in metastatic hormone-sensitive prostate cancer.对于转移性激素敏感性前列腺癌，应首选化疗而非雄激素受体靶向治疗。正方观点：多西他赛化疗应作为转移性激素敏感性前列腺癌的默认治疗方案。
Curr Opin Urol. 2020 Jul;30(4):617-619. doi: 10.1097/MOU.0000000000000777.
7
Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis.多西他赛联合雄激素剥夺治疗联合新型雄激素受体通路抑制剂治疗转移性激素敏感性前列腺癌的系统评价和荟萃分析。
Curr Oncol. 2022 Dec 4;29(12):9511-9524. doi: 10.3390/curroncol29120747.
8
Short-term outcomes of risk-adapted upfront docetaxel administration in patients with metastatic hormone-sensitive prostate cancer: a multicenter prospective study in Japan.在转移性激素敏感性前列腺癌患者中进行风险适应性 upfront 多西他赛治疗的短期结局：日本多中心前瞻性研究。
Med Oncol. 2021 Mar 13;38(4):37. doi: 10.1007/s12032-021-01480-3.
9
Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study.真实世界中阿比特龙与多西他赛一线治疗转移性激素敏感性前列腺癌患者的疗效及医疗成本比较：一项多中心回顾性研究
World J Urol. 2023 Jan;41(1):67-75. doi: 10.1007/s00345-022-04237-3. Epub 2022 Dec 15.
10
Upfront Chemotherapy for Metastatic Prostate Cancer.转移性前列腺癌的一线化疗
Oncology (Williston Park). 2015 Dec;29(12):956-62.
引用本文的文献
1
Comparative Effectiveness of Management Strategies for Stage IV Prostate Cancer: A Narrative Review.IV期前列腺癌管理策略的比较效果：一项叙述性综述
Cureus. 2025 Aug 5;17(8):e89396. doi: 10.7759/cureus.89396. eCollection 2025 Aug.
2
Evolving Treatment Paradigms in Metastatic Hormone-Sensitive Prostate Cancer: Expert Narrative Review.转移性激素敏感性前列腺癌不断演变的治疗模式：专家叙述性综述
Curr Oncol. 2025 Aug 5;32(8):437. doi: 10.3390/curroncol32080437.
3
A modified Delphi consensus regarding the clinical utility of triplet therapy in patients with metastatic hormone-sensitive prostate cancer patients in the UK.英国转移性激素敏感型前列腺癌患者三联疗法临床应用的德尔菲共识改良版。
BMJ Open. 2024 Nov 27;14(11):e090013. doi: 10.1136/bmjopen-2024-090013.
4
Strategic Advances in Combination Therapy for Metastatic Castration-Sensitive Prostate Cancer: Current Insights and Future Perspectives.转移性去势敏感性前列腺癌联合治疗的策略进展：当前见解与未来展望
Cancers (Basel). 2024 Sep 18;16(18):3187. doi: 10.3390/cancers16183187.
5
Role of Lutetium Radioligand Therapy in Prostate Cancer.镥放射性配体疗法在前列腺癌中的作用。
Cancers (Basel). 2024 Jul 1;16(13):2433. doi: 10.3390/cancers16132433.
6
Identifying Suitable Patients for Overcoming Androgen Deprivation Monotherapy in De Novo Metastatic Hormone-Sensitive Prostate Cancer.识别适合在初治转移性激素敏感性前列腺癌中克服雄激素剥夺单一疗法的患者。
J Pers Med. 2024 May 13;14(5):517. doi: 10.3390/jpm14050517.
Zotero 插件